The GRAFT study (PI Cornelius Engelmann, Berlin/ Thomas Berg, Leipzig) was an investigator initiated, multicenter, randomized, controlled trial, which recruited patients with ACLF in 18 German tertiary centers between March 2016 and April 2019. Patient with ACLF aged ≥ 18 were eligible for the trial. Patients were randomized with a 1:1 ratio to receive either standard medical therapy (SMT) (SMT group) or recombinant G-CSF (G-CSF, Ratiograstim®) plus SMT (G-CSF+SMT group). The primary endpoint was defined as transplant-free survival 90 days after inclusion with death and orthotopic liver transplantation (OLT) counting as events.
Modulating innate immune responses in ACLF
Our group is committed to accompanying the GRAFT study with translational research, with experiments continuing far beyond the end of the study. Blood from study patients is assayed and shipped to our laboratory in Berlin for further analysis. The overall aim is to evaluate the clinical relevance of cellular and non-cellular immune responses in ACLF. Clinical evaluations are supplemented by experiments in the mouse model and in vitro. We focus on the importance of purinergic DAMPS and ectonucleotidases, such as CD39, in regulating innate immune responses and modulating exacerbated inflammation in the ACLF. Our study is generously supported by the German Research Foundation (DFG SCHM 2661/3-2).
Nadja Berndt
Student
This website or its third-party tools use cookies, which are necessary to its functioning and required to achieve the purpose illustrated in the Disclaimer. By closing this banner, scrolling this page, clicking a link or continuing to browse otherwise, you agree to the use of cookies.